• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Use of pharmacotherapy for alcohol use disorder in Manitoba, Canada

byAndréa Rondeau-BrownandAlex Chan
September 10, 2021
in Chronic Disease, Psychiatry
Reading Time: 2 mins read
Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment
Share on FacebookShare on Twitter

1. Pharmacotherapy prescriptions for naltrexone, acamprosate, and disulfiram have been proven safe and effective treatments for alcohol use disorder (AUD)

2. Despite this evidence, pharmacotherapy remains underutilized in Manitoba as a treatment plan for AUD. 

Evidence Rating Level: 2 (Good)

Alcohol use disorder (AUD) is a potentially devastating condition leading to significant morbidity and mortality rates in North America. The disorder is characterized by compulsive alcohol use and can lead to various physical diseases, adverse psychosocial and mental health outcomes, and death. Previous studies have found that medications such as naltrexone have been proven to be safe and effective pharmacotherapies for AUD. However, despite the clinical and societal health burden caused by AUD and the existence of these evidence-based medications, the rates of prescription for pharmacotherapy remains low. This population based, longitudinal cohort study examined the use of pharmacotherapy, specifically naltrexone, acamprosate, and disulfiram among individuals with AUD. In order to do so, data was collected between 1996 and 2014 through the Manitoba Population Research Data Repository databases. These databases supplied information on all residents of Manitoba diagnosed with an alcohol use disorder. Next, individuals with AUD were compared between those who received and filled a pharmacotherapy prescription compared to those individuals with AUD who did not. Overall, 2.9% (n=37,388) of the Manitoban population were diagnosed with AUD between 1996 and 2015. Of this cohort, 1.3 % (n=493) of individuals diagnosed with AUD filled a prescription for an AUD medication. The majority of these individuals were males, in urban settings,  receiving their prescriptions from family doctors (53.6%) or psychiatrists (22.3%). The most common medication prescribed for AUD was naltrexone (58%) followed by acamprosate (36.3%) and disulfiram (5.7%). Each of these evidence-based medications were underutilized in Manitoba over the 20-year study period for individuals with AUD. However, a limitation of this study is that it focused solely on pharmacotherapy as a treatment for AUD. In reality, there are many other resources, holistic treatments, support programs, and rehabilitation therapy which may be beneficial to individuals with AUD. When looking specifically at medications, it may appear as though anyone not receiving a prescription is not seeking or receiving aid when in fact, this data was not collected in this study. On the other hand, a strength of this study was its additional analyses of comorbidities such as anxiety disorders or depression. This allowed for a better understanding of the medication’s efficacy in combination with other drugs as well as any contraindications which may decrease prescription rates. Overall, pharmacotherapy drugs such as naltrexone, acamprosate, and disulfiram have been deemed a safe and effective treatment plan for alcohol use disorder. Despite this evidence, individuals living with alcohol use disorder in Manitoba underutilize this treatment option. Alcohol use disorder can have devastating impacts on individuals, their families, and their communities and therefore, more resources, treatment plans, and support is required. Finally, the study highlighted the need for further education for physicians to ensure informed prescribing in order to take an interdisciplinary approach in order to reduce AUD.

Click to read the study in PLOSONE

Image: PD

RELATED REPORTS

Alcohol use declines but remains above pre-pandemic levels

Deficits in executive function are not universal among patients with alcohol use disorder

Few interventions improve posthospitalization follow-up for alcohol use disorder

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: addictionsAlcoholpsychiatry
Previous Post

Interim analysis of rates of adverse events following COVID-19 mRNA vaccination

Next Post

#VisualAbstract: Health wearable devices effectively promote bodyweight in overweight/obese individuals

RelatedReports

Psychiatry

Alcohol use declines but remains above pre-pandemic levels

September 22, 2026
Chronic Disease

Deficits in executive function are not universal among patients with alcohol use disorder

September 15, 2026
Chronic Disease

Few interventions improve posthospitalization follow-up for alcohol use disorder

September 14, 2026
Artificial Intelligence

Universal Health Services acquisition of Talkspace connects virtual and inpatient behavioral care

September 9, 2026
Next Post
#VisualAbstract: Health wearable devices effectively promote bodyweight in overweight/obese individuals

#VisualAbstract: Health wearable devices effectively promote bodyweight in overweight/obese individuals

#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa

#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa

#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer

#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind October 5th, 2026
  • Robotic cholecystectomy benefits high-risk and higher-BMI patients but costs more
  • Antibiotics after appendectomy were not associated with reduced postoperative infections
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.